Chiropractic News | Chiropractic Magazine
Your Online Chiropractic Community
Chiropractic Social Network - Facebook Chiropractic Social Network - Twitter Chiropractic Social Network - Linkedin Chiropractic Social Network - Pinterest Chiropractic Social Network - Google Plus Chiropractic Social Network - YouTube Chiropractic Social Network - RSS
Featured Resources:

Resource Centers:(News, information, and tools to support your practice)

Chiropractic Research

June 2011

Article Tools
Comment on this story

Featured White Paper

Effective treatment of chronic fatigue syndrome, fibromyalgia with D-ribose (Corvalen): a multicenter study


By J. Teitelbaum, MD; R. McGrew1; J. Jandrain1. 1Integrative Therapeutics Inc., Green Bay, WI; Co-sponsored by Integrative Therapeutics Inc. and Bioenergy Inc., Minneapolis, MN

Introduction: Chronic fatigue syndrome and fibromyalgia (CFS/FMS) are debilitating syndromes affecting 2 percent to 4 percent of the population. Although they are heterogeneous con- ditions associated with many triggers, including infections, autoimmune illnesses, hormonal dysfunctions, and other processes, they appear to have the common pathology of being associated with impaired energy metabolism.

As D-ribose (Corvalen) has been shown to increase cellular energy synthesis in heart and skeletal muscle and was shown to significantly improve clinical outcomes in CFS/FMS in an earlier pilot study, we conducted a larger, community based, multicenter trial to see if these findings could be generalized to a broader patient population. We hypothesized that giving D-Ribose would improve function in CFS/FMS patients.


  • A naturally occurring five carbon carbohydrate;
  • Important in energy (ATP) produc- tion, DNA, and RNA function, and other intra-cellular processes;
  • Clinically shown to regenerate ATP levels and improve diastolic function following ischemia/CHF; and
  • Improves symptoms in patients with fibromyalgia/chronic fatigue syndrome.

Study objectives: The study objectives were to determine whether oral D- ribose (Corvalen) administration reduces subjective perceptions of fatigue and improves function in CFS/FMS patients.

Study method: Fifty-three health practitioners enrolled 257

patients who had been diagnosed with fibromyalgia and/or chronic fatigue syndrome. They were given D-ribose (Corvalen), a naturally occurring pentose carbohydrate, at a dose of 5-g TID for three weeks.

All patients were assessed at baseline (one week before treatment was begun) and after one, two, and three weeks of treatment using a visual analog scale (of one to seven points) rating energy, sleep, cognitive function, pain, and overall well-being.

Results: Two-hundred and three patients completed the three week treatment trial. The results showed statistically significant improvement in all five parameters after three weeks of D-ribose (Corvalen) treatment (p < .0001).

Improvement began in the first week of treatment. After three weeks, steady state was not achieved, suggesting that further improvement may occur with longer use. D-ribose was well-tolerated.


  • Oral D-ribose (Corvalen) was well-tolerated with no significant adverse effects.
  • Visual analog scale ratings in sleep, cognitive function, and overall well- being all markedly improved.
  • Improvement was continuing to increase at the end of the three weeks of treatment, suggesting that even greater improvement may occur with longer use.

Conclusion: In this multicenter study, D-ribose (Corvalen) resulted in markedly improved energy levels, sleep, mental clarity, pain relief, and well-being in patients suffering from fibromyalgia and chronic fatigue syndrome.


For more research, visit

This research was provided by Douglas Laboratories.

888-368-4522 •



Be the first to comment on this Article

Limited to 500 Characters. You have characters left.
To submit your comment, please type the security word shown in the picture.
Remember information


Chiropractic Economics Magazine - A Chiropractic Publication

Campaign for Chiropractic

Chiropractic Economics ©2015 | 5150 Palm Valley Rd. Suite 103 | Ponte Vedra Beach, FL 32082 | P:904.285.6020 F:904.285.9944